Pfizer: A 6% Yielding Value Deal

Shares of Pfizer (NYSE: PFE ) have gone nowhere this year, in large part because investors feared a revenue cliff with regard to the company’s COVID-19 products. Although shares have widely disappointed in 2024, I believe Pfizer remains an attractive capitalAnalyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other th ...